Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Min-Su Kang, Jorge Adeva et al.|European Journal of Cancer|2024Cited by 47
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Monica Niger, Francesca Salani et al.|The Oncologist|2024Cited by 10
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The <scp>MAGIC</scp> ‐D IndexMara Persano, Lorenzo Fornaro, Margherita Rimini et al.|Liver International|2025Cited by 9
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational studyMargherita Rimini, Daniele Lavacchi, Lorenzo Fornaro et al.|International Journal of Cancer|2025Cited by 4
Negative impact of corticosteroid use on outcome in patients with advanced <scp>BTCs</scp> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide populationFederica Lo Prinzi, L. Bartalini, Francesca Salani et al.|International Journal of Cancer|2025Cited by 4